Five things for pharma marketers to know: Friday, May 29

Five things for pharma marketers to know: Friday, May 29

Amgen prepares for pricing battle over PCSK9-inhibitor Repatha; Otsuka loses Abilify lawsuit; healthcare and pharma marketers will boost spending on digital advertising in 2015

Teva settles pay-for-delay case for $1.2 billion

Teva reached a settlement with the Federal Trade Commission to resolve an antitrust suit that charged the drugmaker's subsidiary Cephalon with illegally blocking generic competition for narcolepsy drug Provigil.

Five things for pharma marketers to know: Thursday, May 28

Five things for pharma marketers to know: Thursday, May 28

The FBI is investigating Johnson & Johnson's morcellator; Sanofi purchased another priority review voucher; generic drug prices are falling at a slow rate

Mango Health takes on chronic conditions

Mango Health takes on chronic conditions

The updated app now tracks everyday health metrics including weight, activity and glucose levels.

Express Scripts wants cancer drugs to prove value

Express Scripts wants cancer drugs to prove value

The pharmacy benefits manager wants oncology treatments priced according to how well they treat a specific cancer as opposed to using the current one-price-fits-all approach.

Roche diagnostic unit partnering with drugmaker on companion diagnostic

The test seeks to identify patients with metastatic pancreatic cancer and high levels of hyaluronan.

New bill seeks to spur FDA to form clearer social media rules

New bill seeks to spur FDA to form clearer social media rules

Rep. Billy Long introduced legislation that is meant to push the FDA to implement clearer guidelines for regulating drug product information on social media.

Five things for pharma marketers to know: Wednesday, May 27

Five things for pharma marketers to know: Wednesday, May 27

Express Scripts seeks to pay more for top-performing cancer drugs; Olympus plans to settle marketing investigation; Novartis is collaborating on a robotic pill

NPs expand right to practice independently

Twenty states now allow nurse practitioners to practice without an MD affiliation.

ASCO preview: What's coming for lung cancer

ASCO preview: What's coming for lung cancer

A horse race between Merck and Bristol-Myers Squibb, and the importance of one biomarker, will be a focus at the American Society of Clinical Oncology's annual meeting.

Court orders Actavis to keep Namenda IR on market

An appeals court affirmed an earlier ruling that Actavis must keep an older formulation of its Alzheimer's drug, Namenda, on the market.

J&J puts global media business up for review

J&J puts global media business up for review

The review does not include North America, the healthcare giant said.

Five things for pharma marketers to know: Tuesday, May 26

Five things for pharma marketers to know: Tuesday, May 26

Experimental psoriasis drug linked to suicidal thoughts; analysis finds that some high prescribers receive non-research industry money; researchers say new MS drugs spur higher prices of older medications

Five things for pharma marketers to know: Friday, May 22

Five things for pharma marketers to know: Friday, May 22

Amgen's PSCK9 inhibitor gets a position opinion in the EU; the FDA plans to study how spouses influence perception of DTC ads; Botox may relieve depression

21st Century Cures bill advances to House floor

21st Century Cures bill advances to House floor

The legislation would allow drugmakers to share economic information with payers beyond what is included on the FDA-approved label.

OPDP finds fault with Rapaflo website

The FDA's advertising division said images and copy for the BPH drug Rapaflo are misleading.

UCLA looks to Twitter for health trends

UCLA looks to Twitter for health trends

Researchers say Twitter could provide critical insight into health needs for hard-to-reach groups.

Five things for pharma marketers to know: Thursday, May 21

Five things for pharma marketers to know: Thursday, May 21

CVS will buy institutional pharmacy Omnicare in a $12.7-billion deal; ProPublica says the FDA and GlaxoSmithKline failed to protect patients from misusing Advair; Regeneron and Sanofi expect to file RA drug sarilumab with the FDA in the fourth quarter of this year

Giant names Gold as CEO, adds CFO

Giant names Gold as CEO, adds CFO

The West Coast independent agency redefined its leadership team with the appointments of founding principal Steven Gold as CEO and Jeff Nemy as CFO.

Banner triggers OPDP letter to Oak Pharmaceuticals

The FDA's bad-ad group said the banner they saw at a professional conference was misleading.

Five things for pharma marketers to know: Wednesday, May 20

Five things for pharma marketers to know: Wednesday, May 20

FDA official says DTC risk claims are a waste of time; one analyst believes Afrezza could turn around sluggish sales; J&J inks billion-dollar deal to commercialize HCV drugs

Centron scuttles HealthStar name, sells LehmanMillet

Centron scuttles HealthStar name, sells LehmanMillet

The new Centron includes renamed medical education, public relations and market access divisions.

Torres: Career challenges prepared her to take reins at McNeil

Torres: Career challenges prepared her to take reins at McNeil

McNeil Consumer Healthcare president Denice Torres was named woman of the year by the Healthcare Businesswomen's Association.

Cancer center and tech co. test Apple Watch in breast-cancer patients

Cancer center and tech co. test Apple Watch in breast-cancer patients

Parties in the effort say the novelty of wearing an Apple Watch, along with a newly developed app, may help clinicians refine treatment plans and patient support.

Five things for pharma marketers to know: Tuesday, May 19

Five things for pharma marketers to know: Tuesday, May 19

Perrigo says a Mylan deal is possible; new guidelines may reduce cancer screenings; Takeda petitions dictionaries to add a new definition for depression

Inhaled insulin stymied by drive for value

Inhaled insulin stymied by drive for value

Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.

Five things for pharma marketers to know: Monday, May 18

Five things for pharma marketers to know: Monday, May 18

Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition

Makovsky's head of health moving to Finn Partners

Makovsky's head of health moving to Finn Partners

Long-time practice lead Gil Bashe is tasked with unifying and building the health function at global firm Finn Partners.

Five things for pharma marketers to know: Friday, May 15

Five things for pharma marketers to know: Friday, May 15

Genentech alums launch a new biotechnology company; Mallinckrodt sues the FDA over a drug reclassification; Sanofi takes on celiac disease

Contrave dispute causes co-marketer tension

Contrave dispute causes co-marketer tension

An expert tells MM&M a key issue is whether unsubstantiated benefits were used in marketing efforts.

Study: Diagnostics not keeping pace with personalized medicine

Study: Diagnostics not keeping pace with personalized medicine

Precision medicine is a guiding force for many pipelines, but a study shows a gap between developing drugs with biomarkers as well as tests that match patients to treatments.

Five things for pharma marketers to know: Thursday, May 14

Five things for pharma marketers to know: Thursday, May 14

An economist wants $37 billion invested in antibiotic development; Roche plans to file an experimental lung-cancer drug with the FDA this year; Sandoz wants compensation for lost Zarxio sales

Hints from the pros: Social media done well requires risk

Hints from the pros: Social media done well requires risk

Successful social-media engagement is not about the perfect picture or a tightly controlled brand. Instead, panelists at the Hub Convene conference indicated it's a matter of letting the audience take hold

Midwest agency plans to expand to Dallas-Fort Worth

2e Creative will expand to the Dallas-Fort Worth area in a bid to capitalize on the region's growing healthcare landscape.

Five things for pharma marketers to know: Wednesday, May 13

Five things for pharma marketers to know: Wednesday, May 13

FDA panel votes in favor of Vertex's combination cystic fibrosis drug; MannKind blames marketing on slow Afrezza sales; Orexigen draws ire after Contrave study terminated

Everyday Health looks to compete for pharma TV budgets

Everyday Health looks to compete for pharma TV budgets

The digital health firm is expanding services to pharma customers, offering to help drugmakers maximize spending on TV and video.

HHS says Namenda switch could cost $6 billion

The government agency said discontinuing Namenda IR before generic competition enters the market could cost Medicare and its beneficiaries billions over the next decade.

Weight-loss drug prescriptions rise ... slowly

Weight-loss drug prescriptions rise ... slowly

First-quarter results show prescription weight-loss drugs continue to struggle with market and mind share.

Five things for pharma marketers to know: Tuesday, May 12

Five things for pharma marketers to know: Tuesday, May 12

Mylan considers higher bid for Perrigo; Boehringer Ingelheim partners with health system on COPD; EMD Serono's experimental cancer drug gets Fast Track status

FDA panel to review Vertex CF combo therapy on Tuesday

FDA panel to review Vertex CF combo therapy on Tuesday

While the FDA is not required to follow the panel's recommendation, the agency's final decision on Orkambi is crucial to Vertex's future.

Actavis to pursue development of eye drug

Molecular Partners said development for its experimental wet age-related macular degeneration treatment will go forward.

Five things for pharma marketers to know: Monday, May 11

Five things for pharma marketers to know: Monday, May 11

Mylan weighs Teva takeover; GSK and UNC launch research center and drug company; FDA approves Roche colorectal cancer drug diagnostic

Five things for pharma marketers to know: Friday, May 8

Five things for pharma marketers to know: Friday, May 8

Amarin sues FDA over off-label discussions; spike in HCV infections in US blamed on Endo opioid; Pfizer settles gambling, eating and sex addiction lawsuit

WebMD profit jumps 60% in the first quarter

WebMD profit jumps 60% in the first quarter

The company said revenue from pharmaceutical and medical device sponsorships and advertisements rose 10.7% but the company put some initiatives on hold.

Five things for pharma marketers to know: Thursday, May 7

Five things for pharma marketers to know: Thursday, May 7

A court halted the launch of Sandoz's biosimilar; GSK said it is concerned about Advair competition in the US; an FDA panel is expected to vote on a female sexual disorder drug

Sanofi/Regeneron eczema drug could have limited competition

Sanofi/Regeneron eczema drug could have limited competition

About 80% of polled dermatologists told Leerink Partners they would likely prescribe the experimental biologic dupilumab.

Pharma M&A activity reaches new heights this year

Pharma M&A activity reaches new heights this year

Spurred by consolidation, the life sciences industry spent more money on acquisitions in the first quarter than it did in all of 2014 combined.

AbbVie leukemia drug gets breakthrough status

AbbVie expected to submit chronic lymphocytic leukemia drug venetoclax to the FDA this year.

Myriad expands companion diagnostic deals

Myriad expands companion diagnostic deals

The company partnered with AstraZeneca and BioMarin to identify which patients respond to experimental cancer drugs.

Five things for pharma marketers to know: Wednesday, May 6

Five things for pharma marketers to know: Wednesday, May 6

Amgen raises price of Enbrel by 10%; pharma companies appear to raise diabetes drug prices in tandem; Alexion agrees to buy rare-disease drugmaker for $8.4 billion

Study: Considering cost would not change most care decisions

Study: Considering cost would not change most care decisions

A study found that cost-effectiveness and clinical-effectiveness measures often point to the same treatment protocol.

Diabetes advocate Manny Hernandez joins digital health firm

Hernandez is known for his ability to bring together patients and pharma. He joined Livongo Health to aid the firm's user experience.

Five things for pharma marketers to know: Tuesday, May 5

Five things for pharma marketers to know: Tuesday, May 5

Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman

Drugmakers will have to show more than efficacy to justify price

Drugmakers will have to show more than efficacy to justify price

The IMS Institute for Healthcare Informatics says makers of cancer drugs will need more than data points for payers to see the value in their pricey new treatments.

Poll: Patients rely on others to help with OTC choices

Poll: Patients rely on others to help with OTC choices

A Pfizer poll shows patients rely on over-the-counter medications but need help finding the right treatment.

Steal this headline. Win an MM&M Award

Steal this headline. Win an MM&M Award

With 13 categories added in the last two years, there are more ways to win than ever. What could be better? We just extended the entry deadline by a week.

Five things for pharma marketers to know: Monday, May 4

Five things for pharma marketers to know: Monday, May 4

Drugmakers engage early with insurers; patients push for implant to be pulled from the market; about one-third of new drugs qualify for special approval pathways

Fit4D wins MM&M shark-tank challenge

Fit4D wins MM&M shark-tank challenge

Four start-ups presented their business models to pharma executives during the MM&M Transforming Healthcare conference on Thursday in New York City.

Five things for pharma marketers to know: Friday, May 1

Five things for pharma marketers to know: Friday, May 1

Nexium tops the list of Medicare's spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company

Effective communication requires rethinking the patient experience

Effective communication requires rethinking the patient experience

The patient journey concept needs a reboot, according to executives at the inaugural MM&M Transforming Healthcare conference.

Study shows women view health differently than industry thinks they do

Study shows women view health differently than industry thinks they do

A deep dive by the think tank Center for Talent Innovation indicates pharma and payers need to widen their definition of health when communicating with women.

FDA may tighten drug environmental rules

Draft guidance would require applications for drugs that interact with or include hormones to include environmental impact assessments.

Five things for pharma marketers to know: Thursday, April 30

Five things for pharma marketers to know: Thursday, April 30

FDA advisory panel recommends Amgen's T-Vec; Teva again makes the case for a merger with Mylan; the FDA approves injection to treat double chins

Valeant adds commercial expertise in Whitaker

Valeant adds commercial expertise in Whitaker

The drugmaker brought in Anne Whitaker, citing her experience in the gastrointestinal space.

Lawmakers advance 21st Century Cures draft; proposal would allow sharing of off-label economic data

Lawmakers advance 21st Century Cures draft; proposal would allow sharing of off-label economic data

The draft would allow drugmakers to share off-label economic data with payers, a practice that until now has been considered taboo, and require the FDA to assess patient experience data in regulatory decisions, in addition to boosting funding for the NIH.

FDA takes aim at Abilify marketing material

The regulator's marketing watchdog said a sales tool makes promises that the drug's label cannot support.

FDA finalizes biosimilar guidance

The documents acknowledge biosimilars and branded biologics will differ and set assessment standards.

Five things for pharma marketers to know: Wednesday, April 29

Five things for pharma marketers to know: Wednesday, April 29

FDA approves generic Abilify; Mylan raises its offer to buy Perrigo; drugmakers are racing to develop drugs for celiac disease.

Bristol-Myers Squibb sales rise, led by Eliquis and Opdivo

Bristol-Myers Squibb sales rise, led by Eliquis and Opdivo

Newly approved Opdivo added $40 million to the quarter's product sales, which rose 8.9% compared to the year-earlier period.

Pfizer reports uptake for cancer-therapy Ibrance

Pfizer reports uptake for cancer-therapy Ibrance

Sales of the new cancer drug topped expectations since its February launch.

Medtronic agrees to consent decree

The manufacturer's SynchroMed drug-infusion pump was associated with 14 deaths.

PCSK9 antibodies are safe and effective, analysis concludes

PCSK9 antibodies reduced overall mortality and lowered LDL cholesterol levels in more than 10,000 patients in Phase-II/III clinical trials.

Five things for pharma marketers to know: Tuesday, April 28

Five things for pharma marketers to know: Tuesday, April 28

Merck said Januvia is not linked to higher heart-failure risk; Biogen plans to spend $2.5 billion on Alzheimer's disease; Mylan rejected Teva's bid

FDA says Amgen cancer data can't support accelerated approval

FDA says Amgen cancer data can't support accelerated approval

Briefing materials released before Wednesday's panel review indicate the regulator wants clearer data to assess Amgen's experimental melanoma treatment.

Apple Watch — do you love it?

We know it's early days (the smartwatch been available for three days to be exact), but we'd like to know how it is going.

Open Payments database draws 1M visitors

The Centers for Medicare and Medicaid Services last year published 4.45 million records about financial relationships between industry and HCPs.

Five things for pharma marketers to know: Monday, April 27

Five things for pharma marketers to know: Monday, April 27

More pharma companies hike drug prices post-acquisition; HCV linked to increased risk of cancer; a combined Teva-Mylan would control 25% of the US generic drug market

Tecfidera sales slow, Biogen to maintain "significant" sales force

Tecfidera sales slow, Biogen to maintain "significant" sales force

The drugmaker said its top-selling multiple-sclerosis drug Tecfidera's slowdown in sales is due to competition from Plegridy as well as new patient concerns about risks of a rare brain infection.

Five things for pharma marketers to know: Friday, April 24

Five things for pharma marketers to know: Friday, April 24

An AbbVie hep.-C drug nabbed priority review; Merck's hep.-C drug matches efficacy of Harvoni; Mylan increased its bid to buy Perrigo

Merck HCV med's efficacy matches competitors'

Merck HCV med's efficacy matches competitors'

The drugmaker touted new data for its doublet regimen at the International Liver Congress, but it will likely have to look to the margins to find an underserved patient population.

Lilly sees sales fall but reaffirms 2015 revenue guidance

Lilly sees sales fall but reaffirms 2015 revenue guidance

First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.

Mylan's generic Sovaldi launches in India

The hepatitis-C drug is being sold under the name MyHep.

Five things for pharma marketers to know: Thursday, April 23

Five things for pharma marketers to know: Thursday, April 23

Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales

Sales rise as Amgen outlines cardiovascular strategy

Sales rise as Amgen outlines cardiovascular strategy

Established products fueled at 12% jump in first-quarter sales.

Actavis case may not serve as Namenda precedent

A court sided with Actavis in one product-hopping lawsuit for acne drug Doryx.

FDA grants Pfizer lung-cancer drug Breakthrough Designation

Xalkori received the designation to treat a new subset of non-small cell lung cancer patients.

Five things for pharma marketers to know: Wednesday, April 22

Five things for pharma marketers to know: Wednesday, April 22

Study finds vaccines still not linked to autism; investments in healthcare start-ups hit record high this year; biosimilars are already bearing down on prices overseas

Partners+Simons CEO takes helm at parent company Myelin Health

Partners+Simons CEO takes helm at parent company Myelin Health

With new leadership in place, the Myelin Health agency network is seeking to acquire other agencies.

Almost one-third of physicians participated in an ACO last year: Medscape

Despite increasing income, many doctors are turning away from self-employment.

Omnicom reports boost in Q1 net income

The holding company said pharma and health made up 11% of revenues during the first three months of the year.

Five things for pharma marketers to know: Tuesday, April 21

Five things for pharma marketers to know: Tuesday, April 21

Teva proposes acquisition of Mylan; start-up offers BRCA testing for $249; Botox receives another label expansion

Merck files Keytruda for lung cancer, eyes first-line niche

Merck files Keytruda for lung cancer, eyes first-line niche

Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.

FDA takes unusual stance on ALS drug

FDA takes unusual stance on ALS drug

The FDA asked private biotech Genervon to release all available clinical trial data for its experimental ALS treatment.

Conflict-of-interest rules spur $23M investment

Conflict-of-interest rules spur $23M investment

Schools spent $23 million to bring conflict-of-interest policies in line with regulations aimed at ensuring federally funded research is unbiased.

J&J to pay $63M in Motrin case

A Massachusetts court upheld a 2013 decision that the drugmaker failed to provide sufficient risk information for Children's Motrin.

Five things for pharma marketers to know: Monday, April 20

Five things for pharma marketers to know: Monday, April 20

Teva eyes Mylan takeover; Keytruda shown to improve survival, shrink tumors in melanoma; ADHD abuse may follow grads into workforce.

Five things for pharma marketers to know: Friday, April 17

Five things for pharma marketers to know: Friday, April 17

The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down

Bob Finkel launches 'agency alternative'

Bob Finkel launches 'agency alternative'

Kane & Finkel co-founder Bob Finkel launched a healthcare consultancy that will seek out limited-commitment projects.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.